Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it.
Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5 mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Special populations
Renal impairment
Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication helps patients with type 2 diabetes to better control their blood sugar levels while following dietary and exercise therapies. Linagliptin and metformin work together to improve blood sugar levels. Therefore, it serves as a good therapeutic adjunct for those who have difficulty controlling their blood sugar.
How to take
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it.
Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5 mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Special populations
Renal impairment
Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.
Precautions
This medication can cause a rare side effect known as severe lactic acidosis, so caution is required.
It should not be used in patients with an allergy to any of its ingredients, type 1 diabetes, severely impaired kidney function, acute infections, or heart disease.
There is a risk of hypoglycemia, so blood sugar levels should be closely monitored, especially when taken with insulin or sulfonylureas.
Kidney function should be regularly tested, and this medication should not be taken if kidney function is low.
Patients with unstable heart function or acute heart disease should also use this medication with care.
When administering iodine contrast agents used during radiological examinations, the medication should be temporarily discontinued and can be resumed after kidney function has returned to normal.
If surgery is planned, the medication should be stopped 48 hours prior to the surgery and resumed after kidney function has recovered post-surgery.
This medication can cause severe pancreatic diseases such as pancreatitis, so if severe abdominal pain occurs, the doctor should be informed immediately.
Vitamin B12 deficiency may occur, so it is advisable to regularly check blood levels of vitamin B12 if used for long durations.
This medication should be swallowed whole and not crushed, chewed, or split, and while the tablet coating may be excreted in the stool, this is normal.
This medication can interact with other drugs, especially those affecting the kidneys or blood sugar, so caution is recommended when taking them concurrently.
It is advisable not to take this medication during pregnancy or breastfeeding, and those planning to become pregnant should consult a physician.
Elderly patients may have decreased kidney function, so dosage adjustments and regular monitoring of kidney function are required.
In case of overdose, there is a risk of lactic acidosis, and immediate medical treatment should be sought, which may require hemodialysis.
Side effects
Severe lactic acidosis
hypoglycemia
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemic condition
taste disorder
cough
decreased appetite
Show 117 moreCollapse
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulcer
abnormal liver function tests
hepatitis
itching
erythema
rash
bullous pemphigoid
severe and disabling arthralgia
rhabdomyolysis
increased lipolytic enzymes
increased amylase
nasopharyngitis
hypersensitivity reaction
constipation
epigastric pain
enterocolitis
intestinal obstruction
gastroenteritis
shingles
cystitis
acute pyelonephritis
bronchitis
vestibular neuronitis
septicemia
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer-type dementia
chest pain
fever
facial edema
fatigue
chronic obstructive pulmonary disease
asthma
diabetic foot disease
skin lesions
liver metastasis
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
gastric cancer
rectal cancer
pancreatic cancer
meniscus injury
pneumoconiosis
congestive heart failure
angina pectoris
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
dizziness
kidney transplant failure
anxiety
affective disorder
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
chest discomfort
asthenia
pain
nosebleed
oropharyngeal pain
speech disorder
allergic rhinitis
exercise-induced dyspnea
wet cough
runny nose
pulmonary mass
arthralgia
osteoporosis
arthropathy
musculoskeletal discomfort
myositis
myalgias
soft tissue mass
postmenopausal osteoporosis
rotator cuff syndrome
male pattern baldness
hyperhidrosis
hair loss
dermatitis
anxiety
insomnia
depression
hypertension
benign prostatic hyperplasia
stomatitis
mediastinitis
vitreous hemorrhage
fever
ligament sprain
flank pain
myelodysplastic syndrome
vocal fold polyp
confusion state
nocturia
dermatitis
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a sealed container to prevent air or moisture from entering and kept at room temperature between 1 degree Celsius and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness and prevent degradation.
Appearance and packaging
Appearance
White oval-shaped sustained release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.